COCP Cocrystal Pharma Inc

Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference

Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference

– Presentation on Tuesday, February 18th at 11:30 AM ET –

BOTHELL, WA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal, will present at NobleCon16 - Noble Capital Markets’ 16th Annual Investor Conference on Tuesday, February 18, 2020 at 11:30 a.m. ET in Hollywood, Florida.

In addition to the presentation, management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To request a meeting, please contact the NobleCon16 one-on-one desk.



About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit .

Investor and Media Contact:

JTC Team, LLC

(833) 475-8247

EN
11/02/2020

Underlying

COCPCocrystal Pharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cocrystal Pharma Inc

 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Receives IRB Approval from Emory University School of...

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis caused by norovirus infectionThere are no approved treatments or vaccines currently available for norovirus infection BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) an...

December 18, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emergin...

Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern time. The conference is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida. Interested investors and guests of Cocr...

December 1, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Prov...

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026 Granted NIH SBIR award to advance influenza A/B replication inhibitor program BOTHELL, Wash., Nov. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2025, and provides updates on its antiviral product pi...

November 14, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement ...

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (the “Company” or “Cocrystal”) announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39 per unit for proceeds of $1.03 million and unregistered warrant...

October 30, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhi...

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). This approximately $500,000 award will support the Company’s development of a novel, oral, broad-spectrum antiviral candidate for the treatment of influenza A and B infections. Cocrystal plans to utilize these funds to cha...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch